Acorda is an early-stage life science start-up with a promising product that is close to the market (Phase III). The company is how to expand its portfolio of molecules in order to fight the business sustainable. It looks classic in-licensing decisions, including what disease indication, at what stage of development, how many molecules, and under what conditions.

Acorda is an early-stage life science start-up with a promising product that is close to the market (Phase III). The company is how to expand its portfolio of molecules in order to fight the business sustainable. It looks classic in-licensing decisions, including what disease indication, at what stage of development, how many molecules, and under what conditions.
«Hide

from
Fiona Murray,
Marina Kolesnik,
Juan Enriquez,
Jonathan West
Source: Harvard Business School
25 pages.
Publication Date: Jun 24, 2004. Prod #: 604 014 PDF-ENG
Acorda Therapeutics: Rebuilding the Spinal Cord HBR case solution